Tesamorelin vs Ipamorelin: Which Peptide for Which Goal

Tesamorelin and ipamorelin both end in a rise in the body’s own growth hormone, and both get filed under “GH peptides.” The shared label hides what matters. They copy different hormones, act on different receptors and have their evidence in different results: one has phase 3 trials on deep abdominal fat, the other is the cleanest single growth hormone pulse in the class.

Simms Research stocks Tesamorelin at 10mg and 20mg, Ipamorelin at 10mg, and CJC-1295 noDAC / Ipamorelin, a 10mg blend that covers both receptors. The choice comes down to the result a protocol is after, what it costs to run, and whether the two belong together.

What is the difference between tesamorelin and ipamorelin?

The receptor, and with it the job. Tesamorelin is growth-hormone-releasing hormone (GHRH), all 44 amino acids, with a trans-3-hexenoyl cap that shields it from DPP-4, the enzyme that switches GHRH off. As Egrifta it was approved in 2010 after two phase 3 trials shrank the fat around the abdominal organs in adults with HIV-associated lipodystrophy. Ipamorelin is a five-amino-acid ghrelin mimic from Novo Nordisk, which called it the first selective GH secretagogue: as strong as GHRP-6 on growth hormone, with ACTH and cortisol flat. It was never approved.

The somatotrophs, the pituitary cells that make growth hormone, take both signals through separate receptors. GHRH tells them to make and release the hormone; ghrelin triggers a burst and loosens somatostatin, the brake on the system. Tesamorelin, once daily, lifts the whole pattern: in healthy men two weeks of 2mg raised overnight growth hormone, the size of each pulse and the baseline between them, and IGF-1 with them. Ipamorelin gives one sharp pulse. In a 1999 dose-ranging study in volunteers, every dose produced one burst of growth hormone, highest around the 40-minute mark and gone within hours, from a peptide with a two-hour half-life. That is why protocols time it to bedtime.

So neither is a stronger version of the other: one is a daily signal with a body-composition result, the other a short, selective trigger.

Tesamorelin compared to ipamorelin

Receptor, size, evidence and price in one place:

Is tesamorelin or ipamorelin better for belly fat?

Tesamorelin, and it isn’t close. It is the only peptide of either type with phase 3 data on abdominal fat. Across two trials and 816 adults, visceral fat measured by CT fell 18% and 14% over 26 weeks on 2mg daily, while the placebo groups moved +2% and −2%. The scale barely changed: lean mass went up as trunk fat came down. The 2014 liver-fat trial added liver fat, down a net 2.9 points in lipid-to-water percentage over six months. The loss sits in the visceral layer; fat under the skin of the abdomen did not change.

Ipamorelin has no human fat-loss result. Its closest data is a 2001 Cambridge study in mice, where two weeks of ipamorelin twice daily raised food intake and, with it, body weight and body fat, while growth hormone given directly did not. The authors traced the gain to the ghrelin receptor’s appetite signal rather than to growth hormone, which is why ipamorelin is paired for pulse and recovery work, not run alone for fat loss.

For waist and visceral fat, the answer is tesamorelin; the units for the trial dose are in the tesamorelin dosage guide. Body weight itself is a different question, and tesamorelin vs retatrutide sets it against a peptide that moves the scale.

Tesamorelin vs ipamorelin for muscle growth

Tesamorelin again has the measured result, though a modest one. In the phase 3 trials lean mass rose by 1.3kg and 1.2kg over 26 weeks, and a 2026 pooling of five trials put the gain at 1.42kg. In the trial participants whose visceral fat responded, a 2019 reanalysis of the CT scans found the trunk and psoas muscles larger and leaner, with less fat marbled through them. These were adults with HIV, not athletes, and the gain came without any training program attached.

Ipamorelin has no human muscle data. Its growth effects come from Novo Nordisk’s rat work: 15 days of injections three times daily sped bone growth and body-weight gain in step with the dose, without moving total IGF-1. In muscle protocols it supplies the pulse after training, usually through the blend with CJC-1295, on the blend’s post-training schedule.

Can you stack tesamorelin with ipamorelin?

Yes, and on paper it is the best-matched pair among GH peptides, because the two use different receptors. GHRH-type and ghrelin-type signals reinforce each other at the pituitary: in healthy men, low doses of ghrelin given with GHRH drew out more growth hormone than each one alone, summed. Ipamorelin is a ghrelin mimic, so a tesamorelin protocol that adds it gets a larger pulse at the moment of injection without doubling up on either signal.

No trial has run the two together, and every visceral fat figure above is tesamorelin alone. A protocol built to match the trials runs tesamorelin by itself. One that also wants the bigger bedtime pulse adds ipamorelin, each on its own numbers and drawn separately: tesamorelin at 1–2mg, ipamorelin at 100–200mcg, both at night, two hours after food.

Tesamorelin vs CJC-1295/ipamorelin

This matchup is two peptides against one. CJC-1295 is itself a GHRH analogue on tesamorelin’s receptor. The blend’s version has no DAC: GHRH cut to its first 29 amino acids with four of them swapped to resist breakdown, active for about 30 minutes. Every injection of the blend carries a GHRH-type and a ghrelin-type signal; tesamorelin is a single GHRH-type signal backed by the trial results.

Which is stronger, CJC-1295 or tesamorelin?

For visceral fat, tesamorelin, because it has the outcome; there is no head-to-head study. The big CJC-1295 numbers come from its 2006 trial of the DAC version, which binds albumin and lasts about a week: a single shot lifted average growth hormone between two and ten times baseline for at least six days. That is not the form in the blend, and the CJC guide sets out what changes with DAC or without. The no-DAC form has no body-composition trial; its strength comes from landing at the same moment as ipamorelin.

Can you take CJC-1295/ipamorelin and tesamorelin together?

It doubles the half that’s already covered. Tesamorelin and CJC-1295 compete for the same receptor, so the pair gives two GHRH signals and one ghrelin signal. A tesamorelin protocol that wants the second receptor adds plain ipamorelin. The blend makes sense in place of tesamorelin, as the low-cost route to a two-receptor pulse: a $78 vial holds 50 doses of 100mcg + 100mcg. CJC-1295 vs ipamorelin weighs it against plain ipamorelin.

Tesamorelin vs ipamorelin dosage

Tesamorelin is measured in milligrams once daily, ipamorelin in micrograms, often more than once a day:

The ipamorelin dosage chart covers two- and three-dose days, and the blend takes 2.5mL, which puts 100mcg of each peptide at 5 units. The peptide calculator handles any other vial, water or dose, and the reconstitution guide has the mixing steps. Simms Research’s Research Water, $20 for 10mL, is enough for five tesamorelin vials or three of ipamorelin; once mixed, each is good for 28 days refrigerated (more in the storage guide).

Tesamorelin vs ipamorelin cost per month

Tesamorelin costs about six times as much to run. The trial dose uses 60mg a month, and the 20mg vial is the cheaper way to buy it, $7.90 per milligram against $9.50. Ipamorelin is dosed in micrograms: at 200mcg a night one $74 vial holds 50 nights of powder, but a mixed vial is good for only 28 days. Shelf prices, prorated to 30 days:

Tesamorelin vs ipamorelin side effects

Neither gives most people much to notice. Tesamorelin’s reported effects are the ones that follow more growth hormone. Over 26 weeks at 2mg, joint pain came up in 13% of trial participants against 11% on placebo, and swelling in the hands or feet in 6% against 2%, mostly short-lived. Blood sugar rose in a few: 5% reached an HbA1c of 6.5% or more, against 1% on placebo.

Ipamorelin’s record is lighter. In 117 bowel-surgery patients, given about a dozen times the usual research dose twice daily for as long as seven days, adverse events were no more common than on placebo. What protocols notice is a mild pang of hunger soon after dosing, the ghrelin receptor doing its usual work. The warm flush people describe from the blend comes from its CJC-1295 half.

Is tesamorelin better than ipamorelin?

For abdominal fat, yes. For a growth hormone pulse per dollar, no. The goal picks the peptide.

Choose tesamorelin for visceral and liver fat research. It holds the only phase 3 result in this class, a 14–18% drop in deep abdominal fat, with weight flat and a modest lean-mass gain alongside. It is the expensive one, and the result fades once dosing stops, so it suits protocols built to run for months.

Choose ipamorelin for a clean, low-cost growth hormone pulse timed to sleep or training, with cortisol left alone. It has no body-composition outcome of its own, and its appetite signal is a poor fit for a fat-loss protocol run on it alone.

Choose the blend for the bigger two-receptor pulse from one vial, for far less than tesamorelin.

Choose tesamorelin with plain ipamorelin for a visceral fat protocol that also wants the larger bedtime pulse. Pair tesamorelin with ipamorelin, not with the blend, which would double the GHRH side.

How the tesamorelin and ipamorelin batches tested

Both came in over their 10mg labels with purity above 99.5%. An independent ISO-certified lab ran three vials of each current batch in July 2026: tesamorelin averaged 99.55% purity and 11.11mg per vial, ipamorelin 99.77% and 10.32mg. Identity was confirmed by LC-MS, and endotoxin, heavy metals and sterility all passed.

At 11% over its label, tesamorelin is the one where it shows on the syringe: 40 units from a vial mixed with 2mL carries about 2.2mg, and 36 units is the true 2mg. Ipamorelin’s 3% sits inside one unit line. The blend’s current batch measured CJC-1295 at 5.33mg and ipamorelin at 5.28mg, purity 99.93%. The full certificates sit on the tesamorelin, ipamorelin and blend pages and in the lab results index, and the guide to reading a certificate of analysis walks through every field.

Frequently asked questions

Is tesamorelin stronger than ipamorelin?

Not stronger, different. Tesamorelin lifts the whole daily growth hormone pattern and has the trial result on abdominal fat; ipamorelin gives one short, selective pulse per injection and has no body-composition outcome of its own.

Which peptide is better than tesamorelin?

None has stronger visceral fat evidence. For total body weight, the GLP-1 class, retatrutide included, moves the scale far more, while tesamorelin targets the fat around the organs.

Where does sermorelin fit between tesamorelin and ipamorelin?

Sermorelin is the short 29-amino-acid GHRH, the same receptor as tesamorelin for much less money. It has its own comparisons: sermorelin vs tesamorelin, and sermorelin vs ipamorelin, where it appears as ipamorelin’s classic partner.

Are tesamorelin and ipamorelin approved?

Tesamorelin is, as the prescription drug Egrifta for HIV-associated abdominal fat; ipamorelin is not. Both are sold by Simms Research strictly for laboratory research.